A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
This study is currently recruiting participants.
Verified November 2017 by Genentech, Inc.
First Posted: February 15, 2011
Last Update Posted: November 27, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||November 23, 2022|
|Estimated Primary Completion Date:||November 23, 2022 (Final data collection date for primary outcome measure)|